Sökning: "CYP2C9 polymorphism"

Visar resultat 1 - 5 av 11 avhandlingar innehållade orden CYP2C9 polymorphism.

  1. 1. Genetic polymorphisms in breast cancer in relation to risk and prognosis

    Författare :Erika Bågeman; Bröstcancer-genetik; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; age at diagnosis; breast cancer; polymorphism; CYP1A2; IGF1; GSTM1; CYP2C9; CYP2C8; coffee; GSTT1; ER; parity;

    Sammanfattning : Breast cancer is the most common cancer in women living in Sweden and the second most common cancer in the rest of the world. The risk of developing breast cancer is modified by environment, lifestyle, genetics and a combination of these factors. LÄS MER

  3. 2. Cytochrome P450 2C9 polymorphism : interindividual differences in drug metabolism and phenotyping methodology

    Författare :Umit Yasar; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :CYP2C9 polymorphism; phenotyping; genotyping; diclofenac; losartan;

    Sammanfattning : Cytochrome P450 2C9 (CYP2C9) is one of the most important drug metabolizing enzymes in human liver. It catalyses the metabolism of a wide range of different drugs such as S-warfarin, acenocoumarol, losartan, irbesartan, phenytoin, sulphamethoxazole, tolbutamide, glipizide and numerous non-steroidal antiinflammatory drugs. LÄS MER

  4. 3. The in-vitro and in-vivo metabolism of the oral anticoagulant phenprocoumon as influenced by genetic polymorphisms of cytochrome P4502C9

    Författare :Mike Ufer; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Drug metabolism; cytochrome P450; genetic polymorphism; genotyping; CYP2C9; phenprocoumon; warfarin; acenocoumarol; oral anticoagulants;

    Sammanfattning : Oral anticoagulants are widely used for the prevention of thromboembolic disorders. Warfarin (WA) is most commonly used world-wide, while phenprocoumon (PPC) is the first-line anticoagulant in some European countries including Germany. Each anticoagulant exists in two different enantiomeric forms and is administered orally as a racemate. LÄS MER

  5. 4. Cytochrome P450 2C9, 2C19 and 2D6 genetic polymorphisms : evaluation of genotyping as a tool for individualised treatment

    Författare :Maria Gabriella Scordo; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Drug metabolism; CYP2C9; CYP2C19; CYP2D6; genotyping; polymorphism; risperidone; warfarin; fluoxetine; phenytoin; extrapyramidal side-effects;

    Sammanfattning : Recent advances in the understanding of drug metabolism and the molecular biology of CYPs have generated great expectations regarding the use of pharmacogenetic testing as a tool to individualize drug treatment. The individual pharmacogenetic constitution might in principle predict the response to drugs, hormones and toxins. LÄS MER

  7. 5. Pharmacogenetics of drug metabolizing enzymes with special emphasis on Ethiopians

    Författare :Eleni Aklillu; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :Drug metabolism; gene duplication; CYP2D6; CYP2C19; CYP2C9; CYP1B1; CYP1A2; genotyping; xanthine oxidase; ultrarapid metabolizers; polymorphism; caffeine; Ets; dietary selection.;

    Sammanfattning : Pharmacogenetics of drug metabolising enzymes has been well studied in Caucasians and Asians, but relatively little in Africans. The aim of this thesis was to investigate the molecular genetics of drug metabolising enzymes, in particular CYP2D6, CYP2C19, CYP2C9, CYP1B1, CYP1A2 and XO, with special emphasis on the Ethiopian population. LÄS MER